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Abstract Over the past several years there has been intense
effort to delineate the role of epigenetic factors, including
methyl-CpG-binding protein 2, histone deacetylases, and
DNA methyltransferases, in synaptic function. Studies from
our group as well as others have shown that these key
epigenetic mechanisms are critical regulators of synapse
formation, maturation, as well as function. Although most
studies have identified selective deficits in excitatory
neurotransmission, the latest work has also uncovered
deficits in inhibitory neurotransmission as well. Despite
the rapid pace of advances, the exact synaptic mechanisms
and gene targets that mediate these effects on neurotransmis-
sion remain unclear. Nevertheless, these findings not only
open new avenues for understanding neuronal circuit abnor-
malities associated with neurodevelopmental disorders but
also elucidate potential targets for addressing the pathophys-
iology of several intractable neuropsychiatric disorders.
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From the nucleus to the synapse: transcriptional
regulation of synaptic function
The last two decades have witnessed significant advances
in our understanding of gene regulation in neurons. In
particular, synaptic activity has been shown to be a critical
regulator of neuronal gene expression. A number of studies
have focused on the role of synaptic N-methyl-D-aspartic
acid (NMDA) receptors as well as dendritic L-type Ca
2+
channels and their downstream Ca
2+-dependent targets in
regulation of neuronal transcription within the nucleus
(Deisseroth et al. 2003). These processes have been shown
to be essential for long-term neuronal adaptations and
maintenance of synaptic plasticity. However, the impact of
retrograde nuclear signaling and neuronal gene transcrip-
tion on synaptic function has only recently begun to be
elucidated. In this context, Rett syndrome and methyl-CpG-
binding protein 2 (MeCP2)-dependent neuronal gene
regulation have provided a Rosetta stone for how alter-
ations in transcription may impact neuronal function and in
turn affect behavior. These studies highlight the critical role
of epigenetic mechanisms such as histone acetylation and
DNA methylation in the regulation of synaptic function.
Rett syndrome
Rett syndrome (RTT) is a childhood neurological disorder
that is one of the most prevalent causes of mental
retardation and autistic behavior in females (Hagberg et
al. 1983). Individuals affected with RTT typically experi-
ence normal development up to the age of 6–18 months at
which time they fail to acquire new skills and enter a period
of motor skill regression. With time, the RTT defects
become more pronounced and include a wide range of
neurological deficits including stereotypical hand move-
ments, mental retardation, autism-like behavior, seizures,
disturbances of sleep, problems with gait, and decelerated
head growth. Clinical research over the past decade has
demonstrated that RTT is an X-linked disorder that in the
vast majority of cases (>96%) results from heterozygous
mutations in the coding region of the MeCP2 gene (Amir et
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These mutations are predicted to result in loss of MeCP2
function (Ballestar et al. 2000; Yusufzai and Wolffe 2000).
The MeCP2 gene encodes a DNA-binding protein that
binds to methylated cytosines in DNA and then interacts
with a multiprotein corepressor complex containing the
proteins histone deactylases 1 and 2 (HDAC1 and HDAC2)
and Sin3A. Traditionally, MeCP2 is believed to act as a
transcriptional repressor by binding to target gene pro-
moters and silencing their transcription. However, initial
microarray analyses from brain tissue of MeCP2 null
knockout (KO) mice showed only subtle changes in gene
expression and failed to identify genes that are relevant to
the pathology of RTT (Tudor et al. 2002). More recent
microarray data has confirmed the transcriptional repressor
function of MeCP2 and suggests that it may also function
as a transcriptional activator (Chahrour et al. 2008; Lasalle
and Yasui 2009), although it is possible that MeCP2-
dependent transcriptional activation occurs via MeCP2’s
repression of additional transcriptional repressors.
W h i l eM e C P 2i se x p r e s s e di nm a n yt i s s u e s ,i ti s
interesting that the majority of RTT deficits are pronounced
in the central nervous system (CNS). MeCP2 is expressed
at high levels in the mammalian brain, in particular, in
neurons although low levels of expression have been
reported in glia (Ballas et al. 2009). In immature neurons,
MeCP2 expression is low but increases during neuronal
maturation and reaches its highest level of expression in
postmitotic neurons (Kishi and Macklis 2004; Matarazzo et
al. 2004). This developmental profile of MeCP2 expression
may suggest that MeCP2 is involved in neuronal matura-
tion and dendritic arborization (Francke 2006). Interesting-
ly, this high level of MeCP2 expression in postmitotic
neurons continues throughout adulthood suggesting that
MeCP2 may also play an important role in mature neurons.
Attempts to model RTT by generating constitutive
MeCP2 KO mice have resulted in the recapitulation of
some of the neurological symptoms of the disorder,
although these mice die early in postnatal development
precluding behavioral characterization (Chen et al. 2001;
Guy et al. 2001; Tate et al. 1996). Conditional KO mice
were generated to circumvent this complication, in which
floxed MeCP2 mice were crossed with calcium–calmodu-
lin-dependent protein kinase II (CaMKII)-Cre transgenic
mice to selectively delete MeCP2 in brain (Chen et al.
2001). This CaMKII-Cre mouse line expresses Cre recom-
binase in forebrain regions during early postnatal (P14)
development. These conditional MeCP2 KO mice have
many of the behavioral abnormalities that are reminiscent
of the symptoms seen in RTT patients, including impaired
motor coordination, increased anxiety, and abnormal social
interaction with other mice (Gemelli et al. 2006). In a way,
it was rather surprising that deletion of MeCP2 in
postmitotic neurons would recapitulate some of the behav-
ioral phenotypes of RTT and suggests that MeCP2 plays an
important role in mature neurons past neurodevelopment.
What is more, the CaMKII gene is selectively expressed in
excitatory neurons and thus, the fact that deletion of
MeCP2 specifically in this neuronal subtype mimics some
of the disease phenotypes highlights an important role for
excitatory neurons in the etiology of the disorder. Various
other conditional MeCP2 knockout lines have now been
generated and are revealing important temporal and spatial
roles for MeCP2 in the brain. RTT-like phenotypes have
also been observed in mice lacking expression of MeCP2 in
inhibitory GABAergic neurons (Chao et al. 2010), various
aminergic neurons (Samaco et al. 2009), and a subset of
hypothalamic neurons (Fyffe et al. 2008).
While conditional MeCP2 KOs recapitulate many of the
behavioral phenotypes associated with RTT patients, no
major neuroanatomical abnormalities or neuronal loss were
observed in these mice (Chen et al. 2001). Other RTT
mouse models as well as the brains of RTT patients have
not reported any major neuronal loss but rather only slight
reductions in neuronal size and overall brain volume and
subtle changes in neuronal morphology (Kaufmann and
Moser 2000; Kishi and Macklis 2004; Shahbazian et al.
2002). One of the most consistent changes in neuronal
morphology in animal models of the disorder, and
importantly, in postmortem brains of RTT patients, are
alterations in dendritic and synaptic spine structure indic-
ative of a malfunction of synaptic development and
plasticity (Jugloff et al. 2005;K a u f m a n na n dM o s e r
2000). This finding is particularly intriguing since individ-
uals affected with RTT experience normal development up
to a time period that includes pronounced synaptogenesis
and synaptic pruning in cortical regions of the brain, at
which time they then start to manifest the behavioral
phenotypes associated with the disorder. Recent work has
demonstrated that alterations in dendritic structure can
result from changes in synaptic activity (Zito and Svoboda
2002). Therefore, the morphological changes in dendritic
structure in mouse models of the disease, as well as in RTT
patients, may suggest an underlying synaptic deficit in
neurotransmission in the CNS. One focus of our research
has been examining whether the loss of MeCP2 directly
contributes to functional alterations in synaptic transmission
that may ultimately contribute to the disease phenotype.
MeCP2, HDACs, and synaptic transmission
Researchers have started to uncover a number of defects in
synaptic function in three different mouse models of RTT.
The loss of MeCP2 function results in changes in
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long-term synaptic plasticity. Two studies, one using a
MeCP2-null mouse (Asaka et al. 2006) and another using a
mouse expressing a truncated form of MeCP2 (Moretti et
al. 2006), found deficits in both long-term potentiation
(LTP) and long-term depression in hippocampal slices from
these mice. The first study saw these changes only in older,
symptomatic mice (Asaka et al. 2006), while the second
found them also in younger, asymptomatic mice, suggest-
ing the possibility that these synaptic deficits may be
occurring before the manifestation of RTT-like behaviors
(Moretti et al. 2006). Other defects in basal synaptic
transmission were reported in these mice and in additional
studies. In cortical pyramidal neurons, spontaneous and
miniature excitatory postsynaptic current (mEPSC) proper-
ties were reduced in MeCP2 knockout mice while a small
increase was seen in the overall synaptic charge of
spontaneous inhibitor postsynaptic currents (IPSCs; Dani
et al. 2005). In dissociated hippocampal cultures, we found
a significant decrease in the frequency of spontaneous
mEPSCs in MeCP2 knockout versus control neurons while
no change was seen in mIPSC properties (Nelson et al.
2006). These changes in synaptic transmission may be quite
important in underlying mechanisms of neurological dys-
function observed in RTT patients (Table 1). The results
from each of these studies suggest an imbalance between
excitatory and inhibitory activity in the brains of MeCP2
mutant mice, towards less excitation and therefore more
inhibition. Several studies have suggested an abnormal
excitation–inhibition ratio in the brains of autistic patients
(Purcell et al. 2001; Rubenstein 2010; Rubenstein and
Merzenich 2003; Serajee et al. 2003), therefore a similar
imbalance in excitatory–inhibitory neurotransmission may
be common denominator among patients with autism
spectrum disorders including RTT.
Are the deficits in synaptic transmission observed in the
MeCP2 null mice due to MeCP2’s role as a transcriptional
repressor? Previous studies have shown that MeCP2 is a
prototypic member of the methyl-CpG-binding domain
protein family linked with transcriptional repression.
MeCP2 has two functional domains, a methyl-CpG-
b i n d i n gd o m a i n( M B D )a n dat r a n s c r i p t i o nr e p r e s s o r
domain (TRD). The majority of the RTT disease causing
mutations occurs within these functional domains (Amir et
al. 1999; Amir and Zoghbi 2000; Bienvenu et al. 2000;
Huppke et al. 2000; Wan et al. 1999). MeCP2 through its
MBD binding to methylated CpG sites and through its TRD
interacts with a multiprotein corepressor complex that
includes HDAC1 and HDAC2 to silence gene expression
(Nan et al. 1998). HDACs are a family of enzymes that
modulate chromatin plasticity, facilitating protein–DNA
interactions and transcriptional control by catalyzing the
removal of the acetyl group from acetylated lysines of
histone proteins to repress gene expression. Several broad
acting HDAC inhibitor drugs, such as Trichostatin A
(TSA), are commonly used to relieve transcriptional
repression (Jones et al. 1998; Nan et al. 1998).
To examine whether the synaptic deficits observed in
various RTT animal models were due to MeCP2’s role as a
transcriptional repressor, we treated wild-type C57BL/6
hippocampal cultures with HDAC inhibitors, including
TSA, and examined spontaneous neurotransmission (Nel-
son et al. 2006). We found inhibition of HDAC activity
resulted in a similar decrease in mEPSC frequency to that
observed in MeCP2 null neurons. This decrease was
reversed when treatment of C57BL/6 neurons included
both TSA and an inhibitor of transcriptional activation,
actinomycin D, suggesting that newly transcribed genes are
involved in the suppression of synaptic function. Impor-
tantly, this alteration in spontaneous synaptic transmission
was occluded in MeCP2 KO neurons treated with HDAC
inhibitors suggesting that MeCP2 may be responsible for
mediating the alterations in synaptic neurotransmission
through transcriptional repression. If these deficits in
synaptic transmission are mediated through MeCP2’s role
as a transcriptional repressor, then it suggests that specific
synaptic proteins may be MeCP2 target genes that are
altered when MeCP2 function is impaired, as with the
disease causing mutations. One intriguing aspect to this
hypothesis is that the expression of synaptic genes are
tightly controlled and only slight changes in their expres-
sion can profoundly influence synaptic transmission (Kim
et al. 2010), which could be easily missed by a broad scale
microarray approach searching for large changes in gene
expression.
While our data suggests that MeCP2 is functioning as a
transcriptional repressor in the regulation of synaptic
transmission, our data was generated with broad acting
HDAC inhibitors. Since HDAC1 and HDAC2 interact with
DNA through interaction with MeCP2, we took a genetic
approach to more closely examine the impact of impaired
transcriptional repression on synaptic transmission. Rather
surprisingly, these experiments uncovered alterations in
synapse numbers as a result of modifying HDAC activity in
hippocampal neurons (Akhtar et al. 2009). Treatment with
HDAC inhibitors caused a significant increase in excitatory,
but not inhibitory immature synaptic contacts formed
between nascent hippocampal neurons. The increase in
morphological excitatory synaptic markers was coupled
with a robust increase in the frequency of mEPSCs
suggesting an augmentation in functional excitatory synap-
tic contacts. Genetic deletion of both HDAC1 and HDAC2
in immature neurons produced a similar phenotype as that
observed with the pharmacological inhibition of HDAC
activity. Interestingly, double deletion, but not single
deletion, of floxed HDAC1 and 2 using a lentiviral Cre
252 J Neurodevelop Disord (2011) 3:250–256recombinase system was required to trigger a significant
increase in mEPSC frequency, suggesting that both
HDAC1 and HDAC2 are important for controlling synapse
number in immature neurons.
In contrast, in mature hippocampal neurons, treatment
with the HDAC inhibitor TSA or deletion of HDAC2 alone
resulted in a decrease in the frequency of mEPSCs with no
changes in excitatory synapse number (Akhtar et al. 2009;
Nelson et al. 2006). Accordingly, HDAC2 overexpression
caused an increase in mEPSC frequency (Akhtar et al.
2009). Altogether, these data suggest that histone acetyla-
tion can regulate the formation of synapses in hippocampal
neurons, with HDAC1 and HDAC2 playing both redundant
and distinct roles during the time course of neuronal
maturation. Some aspects of basal synaptic transmission,
such as subtle changes in presynaptic neurotransmitter
release, may also be controlled by histone acetylation.
Long-term synaptic plasticity and learning and memory-
related behaviors also appear to be regulated by HDAC
activity. TSA and other broad scale HDAC inhibitors have
been utilized in the brains of mice and were found to
enhance induction of hippocampal LTP and promote
hippocampus-dependent associative memory (Bredy and
Barad 2008; Bredy et al. 2007; Lattal et al. 2007; Vecsey et
al. 2007). A recent study helped delineate which specific
HDAC enzymes are important for bringing about many of
the memory and long-term synaptic plasticity enhance-
ments seen with non-specific HDAC inhibitors. It was
discovered that mice with HDAC2 overexpression, but not
HDAC1, have impaired learning and memory and display
Table 1 Electrophysiological phenotypes of MeCP2 mouse models
Animal model Neuronal preparation Long-term plasticity Basal synaptic transmission Favors excitation
or inhibition
Reference
MeCP2
−/y Cortical slices from
symptomatic mice
a
N/A ↓spontaneous firing (also
in presymptomatic mice
b)
Inhibition Dani et al.
(2005)
↓sEPSC charge
↑sIPSC charge
↓mEPSC amplitudes
Cortical slices from
presymptomatic mice
Normal LTP ↓EPSP amplitudes Inhibition Dani and Nelson
(2009) ↓EPSP amplitude CV
−2
↓Connection probability
Cortical slices from
symptomatic mice
N/A ↓EPSC frequency and
amplitudes
Inhibition Tropea et al.
(2009)
Hippocampal slices
from symptomatic
mice
↓LTP and LTD ↓fEPSP PPR ? Asaka et al.
(2006)
Dissociated hippocampal
cultures
N/A ↓mEPSC frequency Inhibition Nelson et al.
(2006) ↓EPSC PPR
↑10 Hz EPSC amplitude
depression
Autaptic hippocampal
cultures
N/A ↓eEPSC amplitudes Inhibition Chao et al.
(2007) ↓mESPC frequency
↓EPSC charge in response
to hypertonic sucrose
MeCP2
308/y Hippocampal and cortical
slices from symptomatic
mice
Hippocampus: ↓LTP and LTD Hippocampus: fEPSP–
fiber volley slope ratio
? Moretti et al.
(2006)
Cortex: ↓LTP ↓fEPSP PPR
MeCP2
Tg1 Hippocampal slices ↑LTP ↑fEPSP PPR ? Collins et al.
(2004)
Autaptic hippocampal
cultures
N/A ↑eEPSC amplitudes Excitation Chao et al.
(2007) ↑mEPSC frequency
↑EPSC charge in response
to hypertonic sucrose
sEPSC spontaneous excitatory postsynaptic current, sIPSC spontaneous inhibitory postsynaptic current, mESPC miniature excitatory postsynaptic
currents, LTP long-term potentiation, EPSP excitatory postsynaptic potential, CV
−2 inverse square of the coefficient of variation, LTD long-term
depression, fEPSP field EPSP, PPR paired pulse ratio, eEPSC evoked EPSC
a>4 weeks of age
b≤4 weeks of age
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expression of HDAC2 display enhanced hippocampal-
dependent memory formation and LTP, suggesting that
HDAC2 is a negative regulator of memory formation (Guan
et al. 2009). All together, these findings highlight the
importance of histone acetylation and deacetylation in
controlling various aspects of synaptic transmission along
with an animal’s ability to form long-term memories.
DNA methylation and synaptic function
The function of MeCP2 is, at least partially, dependent on
its ability to bind methylated DNA, implicating the
importance of this epigenetic mechanism in synapse
function. DNA methylation negatively regulates gene
expression via the addition of methyl groups at the 5-
position of cytosine residues within CpG dinucleotides of
the promoter regions of genes. In mammals, the enzymes
responsible for establishing and maintaining DNA methyl-
ation patterns are the DNA methyltransferases (DNMTs) 1,
3a, and 3b. DNMT3a and DNMT3b are de novo methyl-
transferases that establish methylation patterns at specific
sites within the genome, while DNMT1 is responsible for
the maintenance of these patterns after DNA replication
(Jaenisch and Bird 2003). DNA methyltransferases, in
particular DNMT1 and 3a, are highly expressed in neurons
in the adult brain, suggesting they may have an important
functional role in postmitotic neurons (Brooks et al. 1996;
Feng et al. 2005; Goto et al. 1994; Inano et al. 2000).
Furthermore, specific neurodevelopment disorders, Rett
syndrome and fragile X syndrome, arise from misinterpre-
tation and dysregulation of DNA methylation, respectively
(Amir et al. 1999; Turner et al. 1996). These observations
have identified a need for understanding the role of DNA
methylation in the mature brain, an area of study that, until
recently, has been largely not studied due to the long-
standing opinion that DNA methylation patterns are
generally static in non-dividing cells (Ehrlich 2003).
The DNA methyltransferases, DNMT1 and 3a, are
highly expressed in adult postmitotic hippocampal neurons
(Feng et al. 2005; Goto et al. 1994), indicating a possible
role for DNA methylation in the control of both synaptic
transmission and learning and memory. We have recently
demonstrated that DNMT inhibition in wild-type hippo-
campal neurons resulted in activity-dependent demethyla-
tion of genomic DNA and a parallel decrease in the
frequency of miniature excitatory postsynaptic currents,
which in turn impacted neuronal excitability and network
activity (Nelson et al. 2008). Treatment with DNMT
inhibitors revealed an activity-driven demethylation of the
brain-derived neurotrophic factor (Bdnf) promoter I, which
was mediated by synaptic activation of NMDA receptors,
as it was susceptible to AP5, a blocker of NMDA receptors.
Interestingly, enhancing excitatory activity, in the absence
of DNMT inhibitors, also produced similar decreases in
DNA methylation and mEPSC frequency, suggesting a role
for DNA methylation in the control of homeostatic synaptic
plasticity. Furthermore, adding excess substrate for DNA
methylation (S-adenosyl-L-methionine) rescued the sup-
pression of mEPSCs by DNMT inhibitors in wild-type
neurons (Nelson et al. 2008). Additional studies have
shown impairments in long-term memory and synaptic
plasticity associated with a decrease in the methylation of
neuronal plasticity genes following inhibition of DNA
methylation (Levenson et al. 2006; Miller and Sweatt
2007). These results demonstrate the importance of main-
taining DNMT activity within mature neurons for proper
synapse functioning. A recent study expanded on these
findings using DNMT1 and 3a conditional KO mice and
found that both enzymes appear to play redundant roles in
the regulation of long-term synaptic plasticity (Feng et al.
2010). One intriguing hypothesis is that the loss of DNMT1
or 3a in hippocampal neurons results in deficits of synaptic
function that lead to an imbalance in excitatory and
inhibitory synaptic transmission, reminiscent of previous
observations in dissociated cultures treated with DNMT
inhibitors (Nelson et al. 2008). DNA methylation induced
changes in basal synaptic transmission could ultimately
lead to additional deficits in synaptic activity and
behavior.
Conclusion
The neurological and neurodevelopmental deficits seen in
patients with Rett syndrome are believed to be a result of
abnormal neuronal gene expression brought about by the
loss of MeCP2 function. Recent studies, including work
from our group, have shown that this altered gene
expression, in turn, triggers various synaptic abnormalities
ranging from deficits in synaptogenesis to control of
neurotransmitter release and long-term synaptic plasticity.
Some of these synaptic modifications can also be mimicked
by manipulation of HDAC enzymes that comprise key
members of the MeCP2 corepressor complex. Furthermore,
inhibition of DNA methyltransferases or other manipulation
of DNMT function can also elicit similar changes in
synaptic function underlying the essential role of MeCP2,
HDACs, and proper DNA methylation regulation in
maintenance and plasticity of central synapses. Although
synaptic molecular targets of these transcriptional mecha-
nisms remain unclear, these findings provide strong
motivation to evaluate therapeutic interventions that may
target the synaptic phenotypes such as augmenting excit-
atory neurotransmission or suppressing inhibitory neuro-
254 J Neurodevelop Disord (2011) 3:250–256transmission to achieve a rebalance of synaptic activity.
Once specific molecular targets are elucidated, ultimately
one can design synapse specific approaches as an effective
complement to the currently expanding repertoire of drugs
targeting nuclear signaling and gene regulation for the
treatment of CNS disorders.
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